Is Bristol-Myers Squibb (BMY) Reasonable After Its 32% Run?

Bristol-Myers Squibb stock has delivered a 31.9% return over the past year, yet its current valuation checks paint a mixed picture rather than a clear bargain or clear overpricing.

• Over the last 12 months, Bristol-Myers Squibb is up 31.9%, which puts recent shareholder returns firmly in positive territory and raises the bar for what counts as good value from here.
• On the supportive side, fresh oncology news such as the FDA accepting the New Drug Application for mezigdomide can underpin expectations for the pipeline, while concerns around patent expirations and trial setbacks remain a key risk that may cap how much investors are willing to pay for the stock.
• The company screens as undervalued on several market based checks, but with a mixed value score of 4 out of 6, the overall verdict is more balanced than that simple label suggests.

For investors, the debate is whether Bristol-Myers Squibb's strong recent share price performance is already reflecting these pipeline milestones and risks, or if the current valuation still leaves room for further upside.

Find out why Bristol-Myers Squibb's 31.9% return over the last year is lagging behind its peers.

Is Bristol-Myers Squibb a Bargain on Earnings?

The P/E ratio is a useful lens for Bristol-Myers Squibb because earnings remain a key anchor for how investors are valuing its established drug portfolio alongside newer oncology assets.

Right now, Bristol-Myers Squibb trades at about 17.0x earnings, compared with an industry average P/E of roughly 15.2x and a broader peer average of 27.5x. The fair P/E ratio implied by its fundamentals is 19.2x, which sits between those benchmarks. That puts the current market multiple at a discount to this fair level and suggests investors are not paying the full price that the model would imply for the company’s earnings profile.

Despite the recent FDA acceptance of the mezigdomide application lifting interest in Bristol-Myers Squibb’s oncology pipeline, the stock still trades below the 19.2x fair P/E that factors in its sector, scale and risk mix. The gap between the current 17.0x and this fair ratio is not extreme, but it does indicate some headroom before the shares would line up with that earnings-based benchmark.

On the P/E multiple alone, Bristol-Myers Squibb stock appears undervalued relative to the earnings-based fair ratio implied by its fundamentals.

See what the numbers say about this price — find out in our valuation breakdown.

The Bristol-Myers Squibb Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Bristol-Myers Squibb's valuation puzzle leaves off. They spell out which combinations of future growth, margins and earnings would need to play out for the stock to be priced meaningfully higher or lower than it is today on the market. Each narrative ties its number to a concrete view of how Bristol-Myers Squibb's growth, profitability and risks could evolve, giving you a clear reference point to revisit as new information comes through.

The community is split on Bristol-Myers Squibb, with one camp seeing pipeline progress as enough to refresh the story while the other focuses on looming patent and pricing pressures.

Bull case: roughly fairly valued

"Robust late-stage pipeline and ongoing life-cycle management for major brands, plus partnerships, expand the breadth of future regulatory approvals and label expansions…"

Read the full Bull Case to see why Bristol-Myers Squibb could be undervalued

Bear case: 32% overvalued

"The impending loss of exclusivity for major blockbusters such as Eliquis, Opdivo, and Revlimid after 2026 will trigger severe revenue cliffs…"

Read the full Bear Case to see why Bristol-Myers Squibb could be overvalued

Do you think there's more to the story for Bristol-Myers Squibb? Head over to our Community to see what others are saying!

The Bottom Line

Bristol-Myers Squibb screens as modestly undervalued on its P/E relative to the earnings profile implied by current fundamentals, but the broader valuation checks are mixed rather than emphatically cheap. That split reflects how much weight you put on the oncology pipeline and life-cycle work on existing drugs versus the risk that patent expiries and pricing pressure chip away at those earnings. The key question from here is whether Bristol-Myers Squibb's pipeline and execution can support the current multiple or even invite a re-rating, or whether the present discount is the market correctly pricing in those longer term competitive and patent risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com